Sanofi-Aventis pharmaceutical company by Ray Sahelian, M.D.
February 10 2016

 

Sanofi SA is a global and diversified healthcare company based in France. The Company focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health.

 

Sanofi-Aventis is the world's third largest drug maker. Sanofi-Aventis (Euronext: SAN, NYSE: SNY), is headquartered in Paris, France. It is a multinational pharmaceutical company. The company is the world's third or fourth largest pharmaceutical company.

 

Sanofi-aventis, headquartered in Paris, France, is in the pharmaceutical industry behind Pfizer and GlaxoSmithKline but above Johnson & Johnson, Merck, AstraZeneca and Novartis. Sanofi-Aventis engages in the research, development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but also in OTC. Sanofi-aventis covers 7 therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines (with its subsidiary Sanofi-Pasteur).


Sanofi-Aventis Medicines

Acomplia anti obesity pill - Sanofi-Aventis has seen strong demand for new obesity pill Acomplia since its launch in Britain in late June, 2006. Acomplia, which switches off brain circuits that make people hungry when they smoke cannabis, is viewed as Sanofi's most important new product, with potential annual sales global of more than $3 billion. As a treatment for obesity, the latest diet-aid drug, Acomplia, produces only moderate weight loss, according to a review of clinical trial results in October 2006. Acomplia, made by Sanofi-Aventis, is known generically as rimonabant. It was approved for use in the European Union earlier in 2006.
   2006 - Sanofi-Aventis's new obesity pill Acomplia is selling well in Britain and Ireland. In Germany, however, insurers have dismissed Acomplia as a "lifestyle" treatment and are refusing reimbursement. Acomplia switches off the same brain circuits that make people hungry when they smoke cannabis.
   2006 - Acomplia (rimonabant) is approved in Mexico to treat obese/overweight patients with associated type 2 diabetes or dyslipidemia or to help them improve glycemic control on background of conventional antidiabetic treatment
   2008 - The Sanofi-Aventis weight loss drug rimonabant does not slow heart disease in obese patients with fat around the middle, and it significantly increases the risk of anxiety and depression. More than 40 percent of patients who take Acomplia, develop psychiatric problems.

   2008 - Sanofi-Aventis SA's weight-loss drug Acomplia has been linked to five deaths and 720 adverse drug reactions in Britain since its launch in 2006. Rimonabant was once seen as a multibillion-dollar seller for the French company but its future has been under a cloud since a panel of U.S. experts rejected it in 2007, amid fears it may cause suicidal thoughts.


Actonel by Sanofi-Aventis competes with Fosamax from Merck
Ambien

Eloxatin cancer drug
Gardasil vaccine - Sanofi-Aventis expects sales of Gardasil, the cervical cancer vaccine it has developed with Merck & Co Inc, to reach as much as 1 billion euros ($1.3 billion) in Europe. Gardasil is a three-dose vaccine that prevents cervical cancer by protecting against the sexually transmitted human papilloma virus (HPV) which causes most cases of cervical cancer and is the second most common cause of death from cancer after breast cancer.
Plavix - A Canadian company little known outside its home country has moved to the forefront in the battle to get cheaper medicines to the public by launching a generic version of the world's second biggest-selling drug. Privately held Apotex Inc. said in August, 2006 that it had launched a generic version of the anti-clotting drug Plavix, which generates annual U.S. sales of about $4 billion for Bristol-Myers Squibb Co. and France's Sanofi-Aventis.

Taxotere cancer drug - In April 2009, FDA regulators cited Sanofi-Aventis SA for circulating a reprinted journal article that overstated the benefits of its breast cancer drug Taxotere. A copy of an article from the Journal of Clinical Oncology described a study of the drug but is "false or misleading" because it makes unsubstantiated claims about Taxotere's benefits over rival drug paclitaxel. Paclitaxel is sold generically by a variety of makers as well as by Bristol-Myers Squibb Co under the brand name Taxol. "These claims misleadingly suggest that Taxotere is superior to paclitaxel in the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, and overstate the efficacy of Taxotere. FDA is unaware of substantial evidence to support these claims," the FDA wrote.